Literature DB >> 10820520

Developmental aspects of lipid and lipoprotein synthesis and secretion in human gut.

E Levy1, D Ménard.   

Abstract

This review article focuses on the ontogeny and the regulatory mechanisms involved in the modulation of the intracellular events governing the assembly and delivery of lipoproteins in human gut. The human fetal intestine organizes villi covered with well-differentiated enterocytes during the end of the first trimester in utero. One striking event is the formation of villi in the colonic mucosa similar to those of the small intestine. The small intestine exhibits very early (14-20 weeks) the capacity to absorb lipids, to elaborate most of the major lipoprotein classes (chylomicrons, very-low-density lipoproteins, low-density lipoproteins, high-density lipoproteins), and to efficiently export these lipoproteins from the intestinal cells. The ontogenic changes of lipid and lipoprotein synthesis are correlated with specific patterns of regulatory enzymes (HMG-CoA reductase, ACAT, MGAT) that are representative of key patterns such as the cholesterol pathway, cholesterol esterification, and neutral lipid pathway. The human fetal colon also has the capability to synthesize lipids, lipoproteins, and apolipoproteins. However, comapred with the small intestine, it is much less efficient at exporting these lipoproteins. Epidermal growth factor, insulin, and hydrocortisone, which are known modulators of the brush border digestive functions of the human gut, differentially modulate the synthesis and secretion of lipoproteins in the small intestine and colon. The use of human fetal gut represents a unique model to further our understanding of the complex biosynthetic molecular events essential for the formation and secretion of lipoproteins relevant to human intestine, both in normal or pathological conditions. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10820520     DOI: 10.1002/(SICI)1097-0029(20000515)49:4<363::AID-JEMT5>3.0.CO;2-2

Source DB:  PubMed          Journal:  Microsc Res Tech        ISSN: 1059-910X            Impact factor:   2.769


  6 in total

Review 1.  Small bowel review: Normal physiology, part 1.

Authors:  Alan B R Thomson; Laurie Drozdowski; Claudiu Iordache; Ben K A Thomson; Severine Vermeire; M Tom Clandinin; Gary Wild
Journal:  Dig Dis Sci       Date:  2003-08       Impact factor: 3.199

2.  Development of the right colon and the peritoneal surface during the human fetal period: human ontogeny of the right colon.

Authors:  Philippe Rigoard; Silke V Haustein; Carole Doucet; Michel Scepi; Jean Pierre Richer; Jean Pierre Faure
Journal:  Surg Radiol Anat       Date:  2009-03-06       Impact factor: 1.246

Review 3.  Insights from human congenital disorders of intestinal lipid metabolism.

Authors:  Emile Levy
Journal:  J Lipid Res       Date:  2014-11-11       Impact factor: 5.922

4.  ApoA-IV modulates the secretory trafficking of apoB and the size of triglyceride-rich lipoproteins.

Authors:  Richard B Weinberg; James W Gallagher; Melissa A Fabritius; Gregory S Shelness
Journal:  J Lipid Res       Date:  2012-01-18       Impact factor: 5.922

5.  Localization, function and regulation of the two intestinal fatty acid-binding protein types.

Authors:  Emile Levy; Daniel Ménard; Edgard Delvin; Alain Montoudis; Jean-François Beaulieu; Geneviève Mailhot; Nadia Dubé; Daniel Sinnett; Ernest Seidman; Moise Bendayan
Journal:  Histochem Cell Biol       Date:  2009-06-05       Impact factor: 4.304

6.  Comparing the intestinal transcriptome of Meishan and Large White piglets during late fetal development reveals genes involved in glucose and lipid metabolism and immunity as valuable clues of intestinal maturity.

Authors:  Ying Yao; Valentin Voillet; Maeva Jegou; Magali SanCristobal; Samir Dou; Véronique Romé; Yannick Lippi; Yvon Billon; Marie-Christine Père; Gaëlle Boudry; Laure Gress; Nathalie Iannucelli; Pierre Mormède; Hélène Quesnel; Laurianne Canario; Laurence Liaubet; Isabelle Le Huërou-Luron
Journal:  BMC Genomics       Date:  2017-08-22       Impact factor: 3.969

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.